Active

Flipping the molecular master switches that drive cancer

Cancer types:

General cancer research

Project period:

Research institute:

The University of Melbourne

Award amount:

£231,415

Location:

Australia

Ricky Johnstone Headshot
Researcher Professor Ricky Johnstone

Professor Johnstone and his team are searching for new ways to switch off the complex web of genes that keep cancer cells surviving and growing.

Hope for the future

Finding out exactly how cancer cells work is vital for understanding what goes wrong in cancer, and how to fix it. We already know that each cancer cell contains thousands of genes, encoded on long strands of DNA, that control how the cell grows. But we don’t yet know exactly how each of these genes work together.


During this project, Professor Johnstone will focus on finding out more about this huge network of genes that help cancer cells survive. He hopes to find brand new combinations of cancer drugs that can switch off the molecules controlling these networks. This vital new information can then be used to develop better and more effective cancer treatments for patients.

Meet the scientists

Professor Johnstone is a fundamental scientist who has dedicated the last 30 years of his professional life to cancer research. Prof Johnstone is a father of three children and keen runner, cyclist and swimmer. Dr Jennifer Devlin leads a small team in Professor Johnstone’s lab. In her spare time Dr Devlin likes to go hiking and explore the bushland around Melbourne.

The science

Genes are a set of molecular instructions that help to regulate how all cells survive and grow. Each gene needs to be switched on at off at different times. This activity is tightly controlled by vast coordinated networks, and regulated by molecular ‘master switches’.


But we don’t yet know exactly how these important master switches are controlled in cancer cells, and Professor Johnstone and his team are using this project to improve our understanding. As part of this work, they will use an innovative new technique to screen a large number of drugs. They hope to find new combinations that can work together to flip the master switches off and stop cancer.


Importantly, the researchers will also investigate which combinations of drugs do not work together. This will help to illuminate in even more detail exactly how gene networks are connected in cancer. Their work will not only help us to understand more about how cancer works and how it can be controlled, but it could also help us find possible new ways to target the disease.

We are very grateful for the Curestarters’ support for innovative and ambitious cancer research. Schemes such as the Worldwide Cancer Research, that fund discovery-based research projects at an international scale, are rare and donations from Curestarters provide important opportunities for scientists to tackle bold research questions.

Ricky Johnstone Headshot
Professor Ricky Johnstone

Related projects

Andres Hidalgo Headshot

Active Spain

Lung cancer

How do cancer cells modify white blood cells to help tumours grow?

Researchers want to help immunotherapy work for more cancer patients by understanding how cancers hijack our immune system and preventing this happening 

Researcher: Dr Andrés Hidalgo

Understanding how cancer cells modify white blood cells to help tumours grow
Andrew Beekman and Team

Active United Kingdom

General cancer research

Can we stop cancer becoming resistant to chemotherapy?

Chemotherapy can sometimes stop working, so this project is hoping to better understand why and find ways to give more, better options to cancer patients.

Researcher: Dr Andrew Beekman

Stopping cancer becoming resistant to chemotherapy
Tim Elliott and Team

Active United Kingdom

General cancer research

Can we predict which patients will respond to immunotherapy?

This project hopes to open up exciting possibilities for personalised cancer treatment by finding how to predict which patients will respond best to treatment.

Researcher: Professor Tim Elliott

Finding ways to predict which patients will respond to immunotherapy
Share this page